David Krempa - Eton Pharmaceuticals Chief Officer
| ETON Stock | USD 14.78 0.10 0.67% |
Executive
David Krempa is Chief Officer of Eton Pharmaceuticals
| Age | 36 |
| Address | 21925 W. Field Parkway, Deer Park, IL, United States, 60010-7278 |
| Phone | 847 787 7361 |
| Web | https://www.etonpharma.com |
David Krempa Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Krempa against Eton Pharmaceuticals stock is an integral part of due diligence when investing in Eton Pharmaceuticals. David Krempa insider activity provides valuable insight into whether Eton Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Eton Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Eton Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Krempa over a month ago Acquisition by David Krempa of 42088 shares of Eton Pharmaceuticals subject to Rule 16b-3 | ||
David Krempa over three months ago Disposition of 20000 shares by David Krempa of Eton Pharmaceuticals at 5.76 subject to Rule 16b-3 | ||
David Krempa over three months ago Acquisition by David Krempa of 42088 shares of Eton Pharmaceuticals subject to Rule 16b-3 | ||
David Krempa over six months ago Acquisition by David Krempa of 144677 shares of Eton Pharmaceuticals at 4.42 subject to Rule 16b-3 |
Eton Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.125) % which means that it has lost $0.125 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.443) %, meaning that it created substantial loss on money invested by shareholders. Eton Pharmaceuticals' management efficiency ratios could be used to measure how well Eton Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of March 2025, Return On Tangible Assets is likely to drop to -0.1. In addition to that, Return On Capital Employed is likely to drop to -0.05. At this time, Eton Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 20th of March 2025, Net Tangible Assets is likely to grow to about 12.2 M, while Non Currrent Assets Other are likely to drop about 10.3 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MBA MA | Replimune Group | N/A | |
| Gary MD | Alector | 63 | |
| David MBA | Inhibrx | N/A | |
| Rocio Hoyos | Kronos Bio | N/A | |
| Colin Love | Replimune Group | 66 | |
| Ashraf Amanullah | Inhibrx | 57 | |
| Corinne Noyes | Lyra Therapeutics | 56 | |
| Christian JD | Gossamer Bio | 58 | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Nina Aragam | Replimune Group | N/A | |
| MPH DO | Kronos Bio | 60 | |
| Lisa CPA | Connect Biopharma Holdings | 48 | |
| Robert Smith | Gossamer Bio | 56 | |
| Michael CPA | Nuvectis Pharma | 49 | |
| MS MBA | Alector | 50 | |
| Emily Hill | Replimune Group | 45 | |
| Jula MD | Travere Therapeutics | 49 | |
| Caryn Peterson | Gossamer Bio | 66 | |
| Angela Giannantonio | Travere Therapeutics | N/A | |
| Carlos Bais | Inhibrx | N/A | |
| Karl Whitney | Passage Bio | N/A | |
Management Performance
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.12 |
Eton Pharmaceuticals Leadership Team
Elected by the shareholders, the Eton Pharmaceuticals' board of directors comprises two types of representatives: Eton Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eton. The board's role is to monitor Eton Pharmaceuticals' management team and ensure that shareholders' interests are well served. Eton Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eton Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Danka Radosavljevic, Senior Operations | ||
| James CPA, Treasurer CFO | ||
| Kevin Guthrie, Executive Operations | ||
| Scott Grossenbach, Senior Operations | ||
| Ingrid Hoos, Senior Affairs | ||
| Ipek ErdoganTrinkaus, Chief Officer | ||
| Sean Brynjelsen, CEO President | ||
| David Krempa, Chief Officer |
Eton Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eton Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.21) % | ||||
| Operating Margin | (0.32) % | ||||
| Current Valuation | 397.42 M | ||||
| Shares Outstanding | 25.84 M | ||||
| Shares Owned By Insiders | 5.38 % | ||||
| Shares Owned By Institutions | 33.23 % | ||||
| Number Of Shares Shorted | 352.98 K | ||||
| Price To Earning | (0.94) X |
Pair Trading with Eton Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eton Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eton Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Eton Stock
| 0.73 | INBX | Inhibrx Symbol Change | PairCorr |
| 0.69 | DSGN | Design Therapeutics | PairCorr |
| 0.66 | EYEN | Eyenovia | PairCorr |
| 0.65 | LFCR | Lifecore Biomedical | PairCorr |
| 0.6 | MRK | Merck Company | PairCorr |
The ability to find closely correlated positions to Eton Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eton Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eton Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eton Pharmaceuticals to buy it.
The correlation of Eton Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eton Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eton Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eton Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share (0.26) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets |
The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eton Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.